18889881171
Kalkine 0
countryflagUS

ACADIA Pharmaceuticals Inc

Healthcare US ACAD

17.34USD
-0.18(1.03%)

Last update at 2025-05-13T18:59:00Z

Day Range

17.1217.61
LowHigh

52 Week Range

14.1532.59
LowHigh

Fundamentals

  • Previous Close 17.52
  • Market Cap3121.51M
  • Volume686678
  • P/E Ratio23.76
  • Dividend Yield-%
  • EBITDA124.54M
  • Revenue TTM929.24M
  • Revenue Per Share TTM5.62
  • Gross Profit TTM 145.49M
  • Diluted EPS TTM0.78

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -213.44400M -167.51900M -280.97300M -234.38300M -243.93600M
Minority interest - - - - -
Net income -215.97500M -167.87000M -281.58400M -235.25900M -245.19200M
Selling general administrative 369.09M 396.03M 388.66M 325.64M 265.76M
Selling and marketing expenses - - - - -
Gross profit 507.07M 465.00M 421.20M 319.48M 205.48M
Reconciled depreciation 2.03M 3.34M 2.93M 2.77M 3.00M
Ebit -225.62200M -173.78300M -289.51800M -249.31100M -250.44900M
Ebitda -223.59600M -170.43900M -286.58600M -246.54500M -247.44400M
Depreciation and amortization 2.03M 3.34M 2.93M 2.77M 3.00M
Non operating income net other - -2.32900M -0.99700M 1.00M -1.84000M
Operating income -223.59600M -170.43900M -286.58600M -246.54500M -247.44400M
Other operating expenses 740.83M 654.58M 728.34M 585.62M 471.25M
Interest expense 6.61M 6.26M 8.54M 14.93M 0.00000M
Tax provision 2.53M 0.35M 0.61M 0.88M 1.26M
Interest income 6.61M 0.59M 6.61M 11.16M 5.35M
Net interest income 6.61M 0.59M 6.61M 11.16M 5.35M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 2.53M 0.35M 0.61M 0.88M 1.26M
Total revenue 517.24M 484.14M 441.75M 339.08M 223.81M
Total operating expenses 730.66M 635.44M 707.79M 566.02M 452.92M
Cost of revenue 10.17M 19.14M 20.55M 19.60M 18.33M
Total other income expense net 10.15M 2.92M 5.61M 12.16M -1.84000M
Discontinued operations - - - - -
Net income from continuing ops -215.97500M -167.87000M -281.58400M -235.25900M -245.19200M
Net income applicable to common shares -215.97500M -167.87000M -281.58400M -235.25900M -245.19200M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 748.96M 587.81M 700.12M 782.62M 783.18M
Intangible assets 65.49M - - 1.11M 2.58M
Earning assets - - - - -
Other current assets 39.09M 21.40M 23.89M 25.69M 18.61M
Total liab 317.20M 187.40M 159.23M 155.61M 84.05M
Total stockholder equity 431.75M 400.41M 540.89M 627.01M 699.13M
Deferred long term liab - - - - -
Other current liab 225.74M 103.58M 80.89M 92.39M 64.17M
Common stock 0.02M 0.02M 0.02M 0.02M 0.01M
Capital stock 0.02M 0.02M 0.02M 0.02M 0.01M
Retained earnings -2430.83700M -2369.55100M -2153.57600M -1985.70600M -1704.12200M
Other liab - 9.07M 7.03M 5.18M 2.86M
Good will 0.00000M - - - -
Other assets - 11.08M 15.98M 54.73M 5.34M
Cash 188.66M 114.85M 147.44M 326.03M 189.68M
Cash and equivalents - - - - -
Total current liabilities 254.25M 125.63M 96.07M 105.97M 74.83M
Current deferred revenue 1.56M - - - -
Net debt -131.45200M -52.84600M -91.30900M -281.56800M -183.31900M
Short term debt 9.40M 9.30M 8.30M 5.09M 3.43M
Short long term debt - - - - -
Short long term debt total 57.20M 62.00M 56.13M 44.46M 6.36M
Other stockholder equity 2862.55M 2770.92M 2694.65M 2612.66M 2402.95M
Property plant equipment - 61.59M 66.31M 9.16M 3.18M
Total current assets 616.12M 507.94M 617.82M 717.62M 760.25M
Long term investments - - - - 2.30M
Net tangible assets - 400.41M 540.89M 625.90M 696.55M
Short term investments 250.21M 301.98M 373.27M 305.93M 507.75M
Net receivables 102.35M 63.08M 65.34M 50.28M 37.87M
Long term debt - - - - -
Inventory 35.82M 6.64M 7.88M 9.68M 6.34M
Accounts payable 17.54M 12.75M 6.88M 8.49M 7.22M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.02M -0.97500M -0.19200M 0.04M 0.30M
Additional paid in capital - - - - -
Common stock total equity - - 0.02M 0.02M 0.01M
Preferred stock total equity - - - - -
Retained earnings total equity - - -2153.57600M -1985.70600M -1704.12200M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 5.10M 18.28M 15.98M 7.45M 7.64M
Deferred long term asset charges - - - - -
Non current assets total 132.83M 79.88M 82.30M 65.00M 22.93M
Capital lease obligations 57.20M 62.00M 56.13M 44.46M 9.79M
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 73.24M -69.98000M 200.10M -164.70700M -69.38500M
Change to liabilities 5.87M -8.21800M 31.16M 12.01M 11.74M
Total cashflows from investing activities 73.24M -71.10200M 192.51M -165.83600M -71.48900M
Net borrowings - - - - -
Total cash from financing activities 8.20M 18.16M 81.00M 371.85M 306.65M
Change to operating activities 27.54M -2.87800M 25.55M 11.08M 4.24M
Net income -215.97500M -167.87000M -281.58400M -235.25900M -245.19200M
Change in cash -32.58900M -178.59300M 137.33M 54.88M 67.69M
Begin period cash flow 153.21M 331.80M 194.47M 139.58M 71.89M
End period cash flow 120.62M 153.21M 331.80M 194.47M 139.58M
Total cash from operating activities -114.03500M -125.66000M -136.16600M -151.13000M -167.47000M
Issuance of capital stock 8.20M 18.16M 81.00M 371.85M 306.65M
Depreciation 2.03M 3.34M 2.93M 2.77M 3.00M
Other cashflows from investing activities - - - -164.70700M 0.04M
Dividends paid - - - - -
Change to inventory 2.42M -4.21000M -3.32000M -1.73700M 1.93M
Change to account receivables 2.17M -16.11900M -12.46600M -9.69100M -8.74700M
Sale purchase of stock - 18.16M 81.00M 371.85M 306.65M
Other cashflows from financing activities 73.24M -71.10200M 192.51M -165.83600M -71.48900M
Change to netincome 61.92M 61.29M 129.98M 81.27M 83.49M
Capital expenditures 0.00000M 1.12M 7.59M 1.13M 2.15M
Change receivables - -15.06200M -12.40800M -10.08500M -9.35900M
Cash flows other operating - 2.67M -4.39500M 3.52M -12.50600M
Exchange rate changes - - - - -
Cash and cash equivalents changes - -178.60000M 137.34M 54.88M 67.69M
Change in working capital 37.99M -24.82400M 11.04M 3.71M -8.19700M
Stock based compensation 68.20M 63.62M 84.42M 82.27M 81.56M
Other non cash items -6.27800M 0.07M 44.28M -4.60700M 1.35M
Free cash flow -114.03500M -126.78200M -143.75300M -152.25900M -169.61800M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ACAD
ACADIA Pharmaceuticals Inc		 -0.18 1.03% 17.34 23.76 26.04 3.36 5.41 2.80 20.92
NVO
Novo Nordisk A/S		 -2.485 3.67% 65.25 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -1.94 2.90% 65.06 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -1.86 0.42% 437.51 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 -4.91 0.85% 570.72 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

ACADIA Pharmaceuticals Inc

12830 El Camino Real, San Diego, CA, United States, 92130

Key Executives

Name Title Year Born
Mr. Stephen R. Davis J.D. CEO & Director 1961
Dr. Srdjan R. Stankovic M.D., M.S.P.H. Pres 1957
Mr. Mark C. Schneyer Exec. VP & CFO 1974
Mr. Brendan P. Teehan Exec. VP, COO & Head of Commercial 1969
Mr. Austin D. Kim Exec. VP, Gen. Counsel & Sec. 1964
Mr. James K. Kihara VP, Chief Accounting Officer & Corp. Controller 1981
Mr. Bob Mischler Sr. VP of Strategy & Technology Operations NA
Mr. Mark C. Johnson VP of Investor Relations NA
Ms. Julie Fisher Sr. VP of Marketing & Commercial Strategy NA
Mr. Rob Ackles Sr. VP & Chief People Officer NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.